Twist Bioscience Corporation $TWST Stake Boosted by Vanguard Group Inc.

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Vanguard Group Inc. grew its holdings in shares of Twist Bioscience Corporation (NASDAQ:TWST - Free Report) by 1.0% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 5,867,459 shares of the company's stock after purchasing an additional 60,276 shares during the quarter. Vanguard Group Inc. owned approximately 9.79% of Twist Bioscience worth $230,356,000 at the end of the most recent quarter.

Other hedge funds have also made changes to their positions in the company. Versant Capital Management Inc increased its stake in Twist Bioscience by 547.2% in the first quarter. Versant Capital Management Inc now owns 686 shares of the company's stock valued at $27,000 after purchasing an additional 580 shares during the last quarter. GAMMA Investing LLC increased its stake in shares of Twist Bioscience by 68.1% during the 1st quarter. GAMMA Investing LLC now owns 748 shares of the company's stock valued at $29,000 after acquiring an additional 303 shares during the last quarter. Banque Transatlantique SA purchased a new position in shares of Twist Bioscience during the 4th quarter worth about $43,000. GF Fund Management CO. LTD. acquired a new stake in shares of Twist Bioscience in the fourth quarter worth approximately $58,000. Finally, Bayforest Capital Ltd grew its holdings in Twist Bioscience by 49.3% in the first quarter. Bayforest Capital Ltd now owns 4,860 shares of the company's stock valued at $191,000 after purchasing an additional 1,604 shares during the period.

Twist Bioscience Stock Up 0.1%

NASDAQ:TWST traded up $0.02 during trading hours on Thursday, hitting $26.47. The stock had a trading volume of 916,200 shares, compared to its average volume of 1,196,109. The company has a market cap of $1.60 billion, a PE ratio of -18.26 and a beta of 2.36. The business has a 50 day simple moving average of $33.78 and a two-hundred day simple moving average of $36.75. Twist Bioscience Corporation has a 1-year low of $24.28 and a 1-year high of $55.33. The company has a current ratio of 3.90, a quick ratio of 3.60 and a debt-to-equity ratio of 0.03.

Twist Bioscience (NASDAQ:TWST - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.54) by $0.07. The business had revenue of $96.06 million during the quarter, compared to analyst estimates of $95.52 million. Twist Bioscience had a negative net margin of 23.51% and a negative return on equity of 29.03%. Twist Bioscience has set its FY 2025 guidance at EPS. Q4 2025 guidance at EPS. Analysts predict that Twist Bioscience Corporation will post -2.12 EPS for the current year.

Insider Activity at Twist Bioscience

In related news, CFO Adam Laponis sold 2,449 shares of Twist Bioscience stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $38.15, for a total value of $93,429.35. Following the completion of the transaction, the chief financial officer directly owned 103,569 shares in the company, valued at approximately $3,951,157.35. This trade represents a 2.31% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Emily M. Leproust sold 1,678 shares of the business's stock in a transaction dated Friday, June 20th. The shares were sold at an average price of $35.76, for a total value of $60,005.28. Following the completion of the sale, the chief executive officer directly owned 645,782 shares of the company's stock, valued at approximately $23,093,164.32. This represents a 0.26% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 6,089 shares of company stock valued at $217,117. Company insiders own 3.01% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the stock. Robert W. Baird cut their price target on shares of Twist Bioscience from $54.00 to $44.00 and set an "outperform" rating on the stock in a research note on Tuesday, May 6th. The Goldman Sachs Group cut their target price on Twist Bioscience from $55.00 to $48.00 and set a "buy" rating on the stock in a research report on Tuesday, May 6th. Guggenheim restated a "buy" rating and issued a $50.00 price objective on shares of Twist Bioscience in a report on Tuesday, May 6th. Evercore ISI set a $46.00 target price on Twist Bioscience in a report on Monday, August 4th. Finally, Cowen restated a "buy" rating on shares of Twist Bioscience in a report on Monday, August 4th. Nine investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Twist Bioscience has a consensus rating of "Moderate Buy" and an average price target of $49.40.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.